Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Bagsværd, Denmark, 8 August 2023 – Hillerød, DenmarkNovo Nordisk's highly advanced plant in Hillerød, Denmark. Novo Nordisk today announced the...
